2-溴-N,N-二乙基乙胺氢溴酸 | 5392-81-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-溴-N,N-二乙基乙胺氢溴酸
• 英文名称: 2-(diethylamino)ethyl bromide
• 英文别名: 2-bromo-N,N-diethylethanamine；diethylamino ethyl bromide；2-bromo-N,N-diethylethan-1-amine；2-bromo-N,N-diethylethylamine；1-Brom-2-diethylamino-ethan
• CAS: 5392-81-4
• 化学式: C₆H₁₄BrN
• 分子量: 180.088
• InChiKey: WRYDGMWSKBGVHS-UHFFFAOYSA-N

物化性质

• 熔点：
  211-215 °C (dec.)(lit.)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险类别码：
  R25,R41,R37/38
• 危险品运输编号：
  UN 2811 6.1/PG 3
• 海关编码：
  2921199090

反应信息

• 作为反应物：
  描述：

  2-溴-N,N-二乙基乙胺氢溴酸 在 sodium hydrogensulfide 、 水 作用下， 生成 bis(2-(N,N-diethylamino)ethyl)sulfide
  参考文献：
  名称：

  M EASUREMENT OF P EDIATRIC I LLNESS S EVERITY U SING S IMPLE P RETRANSPORT V ARIABLES

  摘要：

  Objective: To test the hypothesis that pretransport variables can predict in-hospital mortality that will correlate with major interventions and unplanned events during interfacility transport. Methods: A cohort of children (n = 2,253) transported by a specialized pediatric team to a children's hospital were studied. At the time of referral, data collected included age (months), heart rate, systolic blood pressure, respiratory rate, retractions, stridor or wheezing, seizures, skin perfusion, oxygen requirement, and mental status. Using univariate and stepwise logistic regression, variables predictive of in-hospital mortality were selected from a training set (n = 1,111) and assigned integers based on their computed coefficients. Probability of in-hospital mortality was calculated using the total integer score and age. The risk of mortality derived from the training set was validated in the remaining patients (n = 1,142) by comparing the observed and predicted mortalities. Major interventions performed and unplanned events were determined for each of five predetermined mortality risk groups. Results: Variables (integers) predicting in-hospital mortality included systolic blood pressure (11), respiratory rate (6), oxygen requirement (11), and altered mental status (11). Observed mortality was similar to predicted mortality in all risk categories for the validation sample. As risk of mortality increased, so did the performance of major interventions and the occurrence of unplanned events. Conclusion: Four pretransport variables predicted in-hospital mortality. Risk of mortality correlated with the incidence of major patient interventions, and the occurrence of unplanned events increased as well. This model might be useful in comparing different transport systems using severity-adjusted assessment of children requiring interfacility transport.

  DOI：

  10.1080/10903120190939986
• 作为产物：
  描述：

  二乙氨基乙醇 在 氢溴酸 作用下， 生成 2-溴-N,N-二乙基乙胺氢溴酸
  参考文献：
  名称：

  GB167781

  摘要：

  公开号：
• 作为试剂：
  描述：

  二环己基磷化锂 在 2-溴-N,N-二乙基乙胺氢溴酸 作用下， 以 四氢呋喃 为溶剂， 生成 tetracyclohexyldiphosphine
  参考文献：
  名称：

  Issleib,K.; Rieschel,R., Chemische Berichte, 1965, vol. 98, p. 2086 - 2090

  摘要：

  DOI：

文献信息

• Integrase inhibitors
  申请人：Cai R. Zhenhong

  公开号：US20080058315A1

  公开（公告）日：2008-03-06

  Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.

  三环化合物，其受保护的中间体，以及用于抑制HIV整合酶的方法被披露。
• Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
  申请人：Cai Xiong Sui

  公开号：US20060104998A1

  公开（公告）日：2006-05-18

  The present invention is directed to substituted 4H-chromenes and analogs thereof, represented by the Formula (I): wherein R 1 , R 3 -R 5 , A, D, Y and Z are defined herein. The present invention also relates to the discovery that compounds having Formula (I) are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及被代替的4H-香豆素及其类似物，由式（I）表示：其中R1，R3-R5，A，D，Y和Z在此处定义。本发明还涉及发现具有式（I）的化合物是caspase的激活剂和凋亡诱导剂。因此，本发明的caspase激活剂和凋亡诱导剂可用于诱导在发生细胞不受控制生长和异常细胞扩散的各种临床状况中的细胞死亡。
• 2-ethyl N,N-bis(2-chloroethyl)phosphorodiamidates
  申请人：Laborde Edgardo

  公开号：US20090156559A1

  公开（公告）日：2009-06-18

  2-[2-(Substituted amino)ethyl]sulfonyl}ethyl N,N-bis(2-chloroethyl)phosphorodiamidates and their salts, their preparation and intermediates in their preparation, pharmaceutical compositions containing them, and methods of treatment using them. The compounds are useful for treating cancer and autoimmune diseases, alone and in combination with other therapies.

  2-[2-(取代氨基)乙基]磺酰基}乙基N,N-双(2-氯乙基)磷酰二胺酸酯及其盐，其制备方法和制备中间体，含有它们的药物组合物，以及使用它们的治疗方法。这些化合物可用于治疗癌症和自身免疫性疾病，单独或与其他疗法结合使用。
• Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists
  申请人：Bissantz Caterina

  公开号：US20070027173A1

  公开（公告）日：2007-02-01

  The invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the spiro-piperidine head group A and the residues R 1 , R 2 and R 3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, methods for preparing the compounds and pharmaceutical compositions, and their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.

  本发明涉及作为V1a受体拮抗剂的吲哚-3-基-甲酰基-螺环-哌啶衍生物，其由公式I表示：其中，螺环-哌啶头基A以及残基R1、R2和R3如本文所述定义。本发明进一步涉及含有此类化合物的药物组合物，制备化合物和药物组合物的方法，以及它们在治疗痛经、高血压、慢性心力衰竭、血管升压素不适当分泌、肝硬化、肾病综合征、强迫症、焦虑和抑郁障碍中的用途。
• CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20160031908A1

  公开（公告）日：2016-02-04

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

  揭示了新颖的化合物以及治疗与异常白细胞召集和/或激活相关的疾病的方法。该方法包括向需要的受试者施用代表的化合物的有效量： 或其生理上可接受的盐。

表征谱图